Darifenacin Tablet, Extended Release
NDC 72162-2571
Product Information
Darifenacin is a ANDA-approved product labeled by Bryant Ranch Prepack. Darifenacin is used to treat an overactive bladder. It is supplied as a orange tablet, extended release for oral administration. This product entry covers the primary NDC 72162-2571 and its associated package configuration. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Clinical Specifications
Labeler & Regulatory Data
Marketing Timeline
Product Characteristics
203
Code Structure Chart
Product Details
What is NDC 72162-2571?
What are the uses of this product?
What are Active Ingredients of this product?
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- DARIFENACIN HYDROBROMIDE (UNII: CR02EYQ8GV)
- DARIFENACIN (UNII: APG9819VLM) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- MICROCRYSTALLINE CELLULOSE (UNII: OP1R32D61U)
- FERRIC OXIDE RED (UNII: 1K09F3G675)
- FERRIC OXIDE YELLOW (UNII: EX438O2MRT)
- HYPROMELLOSE 2208 (4000 MPA.S) (UNII: 39J80LT57T)
- HYPROMELLOSE 2910 (15 MPA.S) (UNII: 36SFW2JZ0W)
- MAGNESIUM STEARATE (UNII: 70097M6I30)
- POLYETHYLENE GLYCOL 400 (UNII: B697894SGQ)
- SILICON DIOXIDE (UNII: ETJ7Z6XBU4)
- TALC (UNII: 7SEV7J4R1U)
- TITANIUM DIOXIDE (UNII: 15FIX9V2JP)
What is the NDC to RxNorm Crosswalk for this product?
- RxCUI: 485421 - darifenacin 15 MG 24HR Extended Release Oral Tablet
- RxCUI: 485421 - 24 HR darifenacin 15 MG Extended Release Oral Tablet
- RxCUI: 485421 - darifenacin 15 MG (as darifenacin HBr 17.846 MG) 24 HR Extended Release Oral Tablet
Which are the Pharmacologic Classes of this product?
* Please review the full disclaimer at the bottom of this page.